Siemens Completes the Acquisition of Bayer Diagnostics in Canada
News Jul 04, 2007
According to Siemens, this is a significant milestone, as it positions the Company as a leading provider in the rapidly growing market for molecular diagnostics based on gene analysis.
"We are pleased to have finalized the transaction and feel confident that we will make a major impact in the healthcare industry, with industry leading solutions that aid in the prevention and early detection of disease, diagnosis, therapy and on-going care", said Jim Graziadei, Head of Siemens Medical Solutions Diagnostics, Inc. in Canada.
Graziadei added "With Bayer Diagnostics' previous success as a broad base supplier of solutions to the Central Laboratory, Point of Care, and Molecular labs, and Siemens' comprehensive imaging, therapy, and IT portfolios, Siemens has a unique opportunity to define the future of healthcare."
This set of solutions will enable Siemens' customers to deliver improved personalized care to patients in Canada and around the globe. By uniting the experience, skills, and products to bridge the gap between in-vivo and in-vitro diagnostics, Siemens can partner with customers across the entire healthcare continuum to provide improved clinical, operational, and financial outcomes.
In addition to Jim Graziadei, Head of the newly formed organization, Lisa Pauli, formerly of Siemens Canada Limited, will assume the role of Chief Financial Officer.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.